The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Arsenic trioxide and neuroblastoma cytotoxicity.

På svenska

Author

Summary, in English

The majority of aggressive forms of the childhood tumor neuroblastoma can with current treatment protocols not be cured and possess a major challenge in pediatric oncology. After initial rounds of chemotherapy, surgery and irradiation, which in most cases result in tumor regression, these aggressive neuroblastomas relapse and frequently develop drug resistance. As approximately 50% of the children with neuroblastoma have an aggressive form, there is a compelling demand for new treatment strategies. Arsenic trioxide has the capacity to kill multidrug-resistant neuro-blastoma cells in vitro and in vivo and the drug is currently being evaluated in clinical trials. In this report we discuss the background to the use of arsenic trioxide in cancer therapy and the currently known mechanisms by which arsenic trioxide kills human neuroblastoma cells.

Publishing year

2007

Language

English

Pages

35-41

Publication/Series

Journal of Bioenergetics and Biomembranes

Volume

39

Issue

1

Document type

Journal article review

Publisher

Springer

Topic

  • Cancer and Oncology
  • Pediatrics

Keywords

  • Neuroblastoma
  • Arsenic trioxide
  • Cell death
  • APL
  • Bax

Status

Published

ISBN/ISSN/Other

  • ISSN: 1573-6881